Authors


Shai Friedland, MD

Latest:

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.


Katherine Walsh, MD

Latest:

Preparing and Delivering a Virtual Learning Session

Strategies are important to optimize learning in the virtual environment including speaker preparation, creating a virtual learning climate, and encouraging and enhancing interaction.


Courtney R. Arn, APRN-CNP

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.


Andrew J. Wagner, MD, PhD

Latest:

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.


Cara A. Mathews, MD

Latest:

Dr Mathews on Maintenance Olaparib in Ovarian Cancer

Cara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.


Srikala Sridhar, MD, MSc, FRCPC

Latest:

Dr. Sridhar on the Long-Term Data from the JAVELIN Bladder 100 Trial in Advanced Urothelial Carcinoma

Srikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.


Pashna Munshi, MD

Latest:

Current Treatment Options for Patients with Steroid-Refractory Acute GVHD

Closing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.


Madhurima Anne, MD

Latest:

Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast Cancer

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.



Sarah Sewaralthahab, MD, MPH

Latest:

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.


Ayesha Alvero, MD, MSc

Latest:

Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models

Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.


Laura W. Dillon, PhD, FACMG

Latest:

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.


Ryan Scott

Latest:

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.



The US Oncology Network

Latest:

The US Oncology Network Extends Its Reach into Tennessee with The Addition of Nashville Oncology Associates

The Network continues its strong growth trajectory and its mission to enhance community-based cancer care.


Muhamad Alhaj Moustafa, MD, MS

Latest:

Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCL

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.



William (Bill) Stokes, MD

Latest:

Dr Stokes on Radiation Vs Surgery in HPV+ OPSCC

William (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.


Christopher Wee, MD

Latest:

Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.


Mark Levis, MD, PhD, Johns Hopkins University School of Medicine

Latest:

Final Thoughts on New Developments and Emerging Agents 

Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.  


Paul A. DiSilvestro, MD

Latest:

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.


I-Chia (Daniel) Liu, MD

Latest:

Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal Cancer

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.


Neil H. Bander, MD

Latest:

Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.


Kala Visvanathan, MD, MBBS, MHS

Latest:

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for ​evaluating lipophilic statins in epithelial ovarian cancer. 


Alex McDaniel

Latest:

Seeing Medicine Through the Eye of an Artist

For many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.


Francesco Di Meo, PhD

Latest:

Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple Myeloma

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.


Lori A. Leslie, MD, Hackensack University Medical Center

Latest:

Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLL

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.


Jeremy M. Pantin, MD

Latest:

Dr Pantin on the Evolving Treatment Paradigm in PNH

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.


Adam Bagg, MD, University of Pennsylvania

Latest:

Future Treatment Landscape of AML

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.


Rosa M. Polan, MD

Latest:

Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.